Impact of a short-term nitrate and citrulline co-supplementation on sport performance in elite rowers: a randomized, double-blind, placebo-controlled crossover trial

Viribay, Aitor; Alcántara Alcántara, Juan Manuel; López, Iker; Mielgo Ayuso, Juan; Castañeda-Babarro, Arkaitz

Publication:
Impact of a short-term nitrate and citrulline co-supplementation on sport performance in elite rowers: a randomized, double-blind, placebo-controlled crossover trial

dc.contributor.author	Viribay, Aitor
dc.contributor.author	Alcántara Alcántara, Juan Manuel
dc.contributor.author	López, Iker
dc.contributor.author	Mielgo Ayuso, Juan
dc.contributor.author	Castañeda-Babarro, Arkaitz
dc.contributor.department	Ciencias de la Salud	es_ES
dc.contributor.department	Osasun Zientziak	eu
dc.date.accessioned	2024-09-12T07:41:11Z
dc.date.available	2024-09-12T07:41:11Z
dc.date.issued	2024
dc.date.updated	2024-09-12T07:28:55Z
dc.description.abstract	Purpose: Citrulline (CIT) and beetroot extract (BR) have separately shown benefits in rowing performance-related outcomes. However, effects of combined supplementation remain to be elucidated. The main purpose of this research was to study the effects of 1 week of daily co-supplementation of 3.5 g BR (500 mg NO3−) plus 6 g CIT on aerobic performance, maximal strength, and high-intensity power and peak stroke in elite male rowers compared to a placebo and to a BR supplementation. Methods: 20 elite rowers participated in this randomized, double-blind, placebo-controlled crossover trial completing 1 week of supplementation in each group of study: Placebo group (PLAG); BR group (BRG); and BR + CIT group (BR-CITG). 3 main physical tests were performed: aerobic performance, Wingate test and CMJ jump, and metabolic biomarkers and physiological outcomes were collected. Results: The Wingate all-out test showed no between-condition differences in peak power, mean power, relative power, or fatigue index (P > 0.05), but clearance of lactate was better in BR-CITG (P < 0.05). In the performance test, peak power differed only between PLAG and BR-CITG (P = 0.036), while VO2peak and maximum heart rate remained similar. CMJ jumping test results showed no between-condition differences, and blood samples were consistent (P > 0.200). Conclusion: Supplementation with 3.5 g of BR extract plus 6 g of CIT for 7 days improved lactate clearance after Wingate test and peak power in a performance test. No further improvements were found, suggesting longer period of supplementation might be needed to show greater benefits.	en
dc.description.sponsorship	Open Access funding provided thanks to the CRUE-CSIC agreement with Springer Nature. J.M.A.A. is supported by the Grant FJC2020-044453-I funded by MCIN/AEI/ https://doi.org/10.13039/501100011033 and by 'European Union NextGenerationEU/PRTR'.
dc.format.mimetype	application/pdf
dc.format.mimetype	application/msword
dc.identifier.citation	Viribay, A., Alcantara, J. M. A., López, I., Mielgo-Ayuso, J., Castañeda-Babarro, A. (2024) Impact of a short-term nitrate and citrulline co-supplementation on sport performance in elite rowers: A randomized, double-blind, placebo-controlled crossover trial. European Journal of Applied Physiology, 124(6), 1911-1923. https://doi.org/10.1007/s00421-024-05415-4.
dc.identifier.doi	10.1007/s00421-024-05415-4
dc.identifier.issn	1439-6319
dc.identifier.uri	https://academica-e.unavarra.es/handle/2454/51593
dc.language.iso	eng
dc.publisher	Springer
dc.relation.ispartof	European Journal of Applied Physiology (2024), vol. 124, núm. 6
dc.relation.publisherversion	https://doi.org/10.1007/s00421-024-05415-4
dc.rights	© The Author(s) 2024. This article is licensed under a Creative Commons Attribution 4.0 International License.
dc.rights.accessRights	info:eu-repo/semantics/openAccess
dc.rights.uri	https://creativecommons.org/licenses/by/4.0/
dc.subject	Metabolism	en
dc.subject	Oxide nitric	en
dc.subject	Physiology	en
dc.subject	Supplementation	en
dc.title	Impact of a short-term nitrate and citrulline co-supplementation on sport performance in elite rowers: a randomized, double-blind, placebo-controlled crossover trial	en
dc.type	info:eu-repo/semantics/article
dc.type.version	info:eu-repo/semantics/publishedVersion
dspace.entity.type	Publication
relation.isAuthorOfPublication	81010fc5-9a1b-44dd-8cfe-933acda93159
relation.isAuthorOfPublication.latestForDiscovery	81010fc5-9a1b-44dd-8cfe-933acda93159